Compare PLOW & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLOW | ABUS |
|---|---|---|
| Founded | 1948 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 929.6M |
| IPO Year | 2010 | 2008 |
| Metric | PLOW | ABUS |
|---|---|---|
| Price | $44.18 | $4.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $51.50 | $5.00 |
| AVG Volume (30 Days) | 189.9K | ★ 2.0M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $656,053,000.00 | $14,083,000.00 |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $5.36 | $239.71 |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | 15.40 | ★ 128.21 |
| 52 Week Low | $25.38 | $3.04 |
| 52 Week High | $48.47 | $5.10 |
| Indicator | PLOW | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 52.68 |
| Support Level | $28.78 | $4.42 |
| Resistance Level | $47.58 | $4.64 |
| Average True Range (ATR) | 1.53 | 0.20 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 9.77 | 56.76 |
Douglas Dynamics Inc is a manufacturer and upfitter of commercial vehicle attachments and equipment. The Company's portfolio includes snow and ice management attachments sold under the BLIZZARD, FISHER, HENDERSON, SNOWEX, and WESTERN brands, turf care equipment under the TURFEX brand, and industrial maintenance equipment under the SWEEPEX brand. The Company's portfolio also includes the upfit of attachments and storage solutions under the HENDERSON brand, and the DEJANA brand and its related sub-brands. The Company also leases fifteen manufacturing upfit and service facilities located in Iowa, Maryland, Missouri, New Jersey, New York, Ohio, Pennsylvania, and Rhode Island. The Company conducts business in two segments: Work Truck Attachments and Work Truck Solutions.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.